US biotech firm Gilead Sciences announced plans Monday to acquire rival Pharmasset, a group specializing in treatments for AIDS and hepatitis, for $11 billion. The deal at $137 per share "represents an important and exciting opportunity to accelerate Gilead's effort to change the treatment paradigm for HCV (hepatitis C virus) infected patients by developing all-oral regimens for the treatment of the disease regardless of viral genotype," California-based Gilead said.
GMT 10:31 2018 Tuesday ,13 November
Russian police uproot 70 underground drug labs in past six monthsGMT 16:32 2018 Tuesday ,06 November
Rwanda aims to achieve universal access to clean water by 2024GMT 16:57 2018 Sunday ,04 November
Palestinian women witness higher cure rate of breast cancerGMT 13:11 2018 Tuesday ,30 October
Emergency surgery saves life of touristGMT 10:44 2018 Tuesday ,23 October
Scientists find microplastics in human stool for first timeGMT 09:18 2018 Tuesday ,23 October
US judge upholds Monsanto weedkiller cancer verdict, reduces payoutGMT 14:22 2018 Friday ,19 October
Birth spacing ‘improving health of Omani women’GMT 15:40 2018 Monday ,15 October
Pakistani president launches nationwide anti-measles driveMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor